Clinical Trials Browser

INDUSTRY × niraparib × Breast × Clear all

Breast Neoplasms, Neoplasm Metastasis

NCT05169437 2025-10-29

PAVO

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

30 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04915755 2025-07-16

ZEST

Phase 3 Active not recruiting

40 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03329937 2025-01-08

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

Phase 1 Completed

21 enrolled 12 charts

Breast

Breast Neoplasms

NCT05261269 2023-12-13

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Phase 1 Completed

30 enrolled

Breast

HER2-negative Metastatic Breast Cancer

NCT02657889 2022-12-01

TOPACIO

Phase 1/2 Completed

122 enrolled 29 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01905592 2022-11-15

BRAVO

Phase 3 Terminated

216 enrolled 19 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04655183 2021-06-30

Study of M4344 in Combination With Niraparib

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

PAVO

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

ZEST

Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

TOPACIO

BRAVO

Study of M4344 in Combination With Niraparib